Abstract: An aromatic amine derivative represented by the following formula (1), wherein at least one of Ar1 to Ar3 is represented by the following formula (2), wherein X1 to X3 are independently a nitrogen atom or CR2, provided that two of X1 to X3 are a nitrogen atom and X1 and X3 are not simultaneously a nitrogen atom.

Abstract: The invention describes the development of highly efficient, recyclable two component system, CuAl-hydrotalcite/rac 1,1?-Binaphthalene-2,2?-diol catalytic system for the N-alkylation of electron deficient aryl chlorides in presence of potassium carbonate as a base at room temperature in 3-6 h, wherein the process is provided for the preparation of various secondary amines via C—N coupling reaction of aliphatic amines(aliphatic open chain, acyclic, benzyl amines and heterocyclic amines) with various aryl chlorides.

Abstract: HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.

Abstract: Disclosed are compounds represented by structural formula (I): methods of producing compounds represented by structural formula (I), and their use in inhibiting oxidation in an oxidizable material.

Abstract: The present invention relates to a N-(Phenylcycloalkyl)carboxamide or N-(Benzylcycloalkyl)carboxamide or its thiocarboxamide derivative of formula (I) wherein A represents a carbo-linked, unsaturated or partially saturated, substituted or non-substituted 5-membered heterocyclyl group, T represents an oxygen or a sulphur atom, B represents a non aromatic carbocycle that can be substituted by one to four C1-C8-alkyl groups, and X, Z1, Z2 and Z3 represent various substituents; their process of preparation; the preparation of intermediate compounds; their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

Abstract: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

Abstract: A process is provided for the preparation of 1,3-diamino-4,6-dinitrobenzene by amination of 1,3-dihalo-4,6-dinitrobenzene. The presence of water advantageously results in a highly pure product, free or essentially free of glycol ether impurities.

Abstract: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states.

Abstract: Curative fibre components comprise one or more fibres for filaments of curative suitable to cure curable resins such as thermoset resin. In curative fibre components comprising a plurality of fibres of curative, the fibres can be commingled, such as twisting, to form a thread or yarn. Curative fibre components can be used to form a material in the form of a sheet, fabric, layer, textile or mat of woven or non-woven curative fibres. Curative fibre components can be used to produce composite materials such as fibre reinforced resinous composite materials. The curative fibre components can be commingled, including interwoven, stitched and layered with other fibres or fibrous materials, such as fibrous reinforcement, fibrous curable resin, fibrous thermoplastic, other non-reinforcing fibres to form composite materials, prepregs, preforms and articles.

Abstract: The present invention describes indenofluorene derivatives of the general formula I, II, III or IV having emitting and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electro-luminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.

Abstract: The present invention describes indenofluorene derivatives containing a heteroaromatic bridge atom as a novel class of materials having emitting and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.

Abstract: Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amido group is introduced is coordinated, a catalyst composition including the same, and an olefin polymer using the catalyst composition. The transition metal complex has a pentagon ring structure having an amido group connected by a phenylene bridge in which a stable bond is formed in the vicinity of a metal site, and thus, a sterically hindered monomer can easily approach the transition metal complex. By using a catalyst composition including the transition metal complex, a linear low density polyolefin copolymer having a high molecular weight and a very low density polyolefin copolymer having a density of 0.910 g/cc or less can be produced in a polymerization of monomers having large steric hindrance. Further, the reactivity for the olefin monomer having large steric hindrance is excellent.

Abstract: The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective ?-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for ?-2 over ?-1 adrenergic receptors or ketamine at specific pH. The compositions preferably comprise brimonidine and/or dexmedetomidine and/or ketamine.

Abstract: This invention discloses a process for manufacturing an elastomeric article by liquid injection molding, said process comprising the steps of: (I) heating a curable composition comprised of (1) a liquid polymer comprised of repeat units that are derived from a conjugated diolefin monomer, wherein said liquid polymer has a weight average molecular weight which is within the range of 5,000 to 100,000, and wherein the liquid polymer is functionalized with an amine moiety, (2) a carbonyl inhibited platinum catalyst, and (3) a tetrakis(dialkyl siloxy) silane crosslinking agent, to a temperature which is within the range of 30° C. to 100° C.; (II) injecting the heated curable composition into a mold at a temperature which is within the range of 100° C. to 210° C. to produce the elastomeric article; and (III) removing the elastomeric article from the mold.

Abstract: This invention relates to a process for preparing functionalized aryl, heteroaryl, cycloalkenyl, or alkenyl compounds, by a transition-metal-catalyzed cross-coupling reaction of a substituted or unsubstituted aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide, where X is a halide, diazonium, tosylate (p-toluenesulphonate), mesylate (methanesulphonate) or triflate (trifluoromethanesulphonate) leaving group.

Abstract: Methods are provided for preparing branched alkyl-substituted-anilines, such as 2-(1,3-dimethylbutyl)aniline. Such methods comprise combining aniline, an alkyl-substituted-1-alkene, such as 4-methyl-i-pentene, and an aluminum alkyl catalyst.

Abstract: The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the compound of formula (I) is a compound of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A and B each represents a radical of formula and wherein —C-D- represents a bivalent radical of formula —N?CH—NR17—??(c-1); or —NR17—CH?N—??(c-2); provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).

Abstract: This disclosure relates to a static phosgene mixer, and more generally, to an apparatus for mixing of fluid components such as phosgene and amine during an highly reactive, chemical reaction that is vulnerable to the creation of undesired by-products, and equipment fouling. A guide element is disposed in the static mixer to divert the incoming flow of phosgene around the guide element and create an annular mixing passage in the static mixer. This allows for the use of an increased external radius of the effective phosgene flow while maintaining phosgene velocity by creating a blockage of the flow. The same flow, when transformed from a circular configuration to an annular configuration has an increased external radius, and a greater quantity of MDA jets can be placed along the increased radius, thus increasing the overall homogeneity of the mixture.

Abstract: Diaromatic amine compounds or an isomer or isomeric mixture thereof is provided having the general formula: wherein n, m, R, R1, R2, R3, R4 and R5 are as defined herein are provided. Lubricating oil compositions and stabilizer-containing compositions containing the diaromatic amine compounds are also provided.

Abstract: A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative.

Abstract: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.

Abstract: The present invention relates to biaryl carboxylic acid compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing these compounds and methods of treating diseases which express the Mcl-1 protein.

Abstract: An ethylene compound having general formula (I) below: wherein R1, R2 and R3 are each independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons or an alkoxyl group of 1 to 6 carbons; R4 is an alkyl group of 1 to 3 carbons, phenyl or tolyl; and Ar is an aryl group of 7 to 20 carbons or a heterocyclic group, functions as a charge transport material in an electrophotographic photoreceptor. This compound suppresses photodeterioration, causes little light-induced fatigue, can prevent a rise in the residual potential associated with such light-induced fatigue, has stable properties as an electrophotographic photoreceptor even when used for an extended period of time, and is able to stably provide a satisfactory image.

Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Abstract: The present invention provides a novel transition metal complex where a monocyclopentadienyl ligand to which an amido group is introduced is coordinated, a method for synthesizing the complex, and olefin polymerization using the same. The method for preparing a transition metal complex according to the present invention comprises a step of blocking a by-reaction of a nitrogen atom using a compound containing a protecting group, and thus it is possible to prepare a transition metal complex in a simpler manner in a high yield. Further, the transition metal complex according to the present invention has a pentagon ring structure having an amido group connected by a phenylene bridge in which a stable bond is formed in the vicinity of a metal site, and thus, sterically monomers can easily approach the transition metal complex.

Abstract: The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

Abstract: The present invention relates to novel compounds and compositions comprising novel oligomers and polymers, and electronic device comprising at least one layer containing the compositions. The novel oligomers and polymers can be solubilized, and can be used in solution to form electronic devices. The compounds can function as monomers, and copolymers can be formed from such monomers, such copolymers comprising, as polymerized units, a plurality of units of the compounds.

Abstract: A photoelectric conversion element is disclosed, comprising a compound represented by the following formula between a pair of opposed electrodes: wherein Ar1, AR2 and Ar3 are each a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, x is an organic residue having an acidic group and n is an integer of 2 to 8. A solar cell comprising the photoelectric conversion element is also disclosed.

Abstract: The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Abstract: This invention provides alignment materials for liquid crystal display device of vertical alignment mode and methods for the preparation of the same, and more particularly, it provides diaminobenzene derivatives represented by the following formula 1 (shown in description), capable of aligning liquid crystal in uniform and vertical way and remarkably improving clarity and solubility against organic solvents, methods for the preparation of the same and liquid crystal alignment films using the same.

Abstract: The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells.

Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Abstract: A methylol compound having a specific formula such that two triphenylamine groups each having two methylol groups are connected with each other by an oxygen atom, a methylene group, a vinylene group, or an ethylene group. The methylol compound is preferably prepared by subjecting a corresponding aldehyde compound to a reduction reaction in the presence of a reducing agent. The methylol compound is preferably used as a charge transport material.

Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.

Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Abstract: The present invention relates generally to catalysts and processes for the Z-selective formation of internal olefin(s) from terminal olefin(s) via homo-metathesis reactions.

Abstract: This invention discloses a process for making dilithium initiators in high purity. This process can be conducted in the absence of amines which is desirable since amines can act as modifiers for anionic polymerizations. The dilithium compounds made are highly desirable because they are soluble in aromatic solvents.

Abstract: 2-(3-Aminobenzoyl)-3-cyclopropyl-3-oxopropanenitriles of the formula (I) are described as herbicides. In this formula (I), X and Y are organic radicals such as alkyl and other radicals such as halogen, nitro and cyano.

Abstract: A process for preparing a compound of formula (V) or its enantiomer, which comprises: (a) reacting racemic aminoindan of formula (II) or its enantiomer with allylhalide in presence of a base and an organic solvent at a temperature ranging from 25 C to the reflux temperature of the solvent to give compound of formula (III); Where R is H or (b) reacting the compound (III) with halogenating agent in a suitable organic solvent to give a dihalo compound of formula (IV). (c) treating the dihalo compound (IV) with a suitable base to give compound (V).

Abstract: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules.

Abstract: The present invention is directed to Form II, III, IV and V of sertraline hydrochloride and methods for its preparation. According to the present invention, the various polymorphs of sertraline hydrochloride may be produced either, directly from sertraline base or sertraline acetate.

Abstract: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for the preparation of the compound of Formula (I), characterization of polymorphs of the FAAH inhibitor, and their uses therof.

Abstract: The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) (Captodiamine).

Abstract: The invention relates to a process for the work-up of residues from the production of isocyanates, which comprises the steps: a) hydrolysis of the residues by means of water, b) introduction of the reaction product from step a) into a mixer having a heat transfer surface, c) separation of amine and water from the output from step b), d) separation of water and amine.

Abstract: The present invention relates to a chromatography ligand defined by the following formula (I) R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.

Abstract: A method for producing a compound having a deuterated aromatic ring or heterocyclic ring according to the invention includes heating a compound having an aromatic ring or heterocyclic ring in the presence of heavy water, a transition metal and a metal which generates deuterium. As the metal which generates deuterium, at least one metal selected from the group consisting of aluminum, magnesium, zinc, iron, lead and tin is preferred. As the transition metal, at least one metal selected from the group consisting of platinum, palladium, ruthenium and rhodium is preferred. The heating is preferably carried out by microwave irradiation.

Abstract: A process for producing 6-dimethylaminomethyl-1-(3-hydroxy- or 3-C1-C4 alkoxyphenyl)-cyclohexane-1,3-diols from 6-dimethylaminomethyl-1-hydroxy-1-(3-hydroxy- or 3-C1-C4 alkoxyphenyl)-cyclohexane-3-ones by catalytic hydrogenation in the presence of heterogeneous or homogeneous catalysts, or by using metal hydrides.

Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

Abstract: New anti-oxidation and/or anti-corrosion agents representing new products resulting from the reaction of a diphenyl amine compound (DPA) with a phenyl-?-naphthyl amine compound (PAN), possess improved properties, as compared to known additives. Lubricating compositions, in particular for turbines, containing the novel anti-oxidation and/or anti-corrosion agents, and a method for preparing the novel anti-oxidation and/or anti-corrosion agents, as well as the novel lubricating compositions are described.